Literature DB >> 3081088

Irreversible pulmonary hypertension after treatment with fenfluramine.

J McMurray, P Bloomfield, H C Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3081088      PMCID： PMC1339211          DOI： 10.1136/bmj.292.6515.239-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Haemodynamic effects of oral aminorex and amphetamine in unanaesthetized beagle dogs.

Authors:  J A Will; G E Bisgard
Journal:  Thorax       Date:  1972-01       Impact factor: 9.139

2.  [Are the primary vascular forms of chronic pulmonary heart disease becoming more common?].

Authors:  H P Gurtner; M Gertsch; C Salzmann; M Scherrer; P Stucki; F Wyss
Journal:  Schweiz Med Wochenschr       Date:  1968-10-12

3.  [A case of chronic pulmonary hypertension after fenfluramine intake].

Authors:  G Gaul; G Blazek; E Deutsch; H Heeger
Journal:  Wien Klin Wochenschr       Date:  1982-11-26       Impact factor: 1.704

4.  Primary pulmonary hypertension: natural history and the importance of thrombosis.

Authors:  V Fuster; P M Steele; W D Edwards; B J Gersh; M D McGoon; R L Frye
Journal:  Circulation       Date:  1984-10       Impact factor: 29.690

5.  Pulmonary hypertension and fenfluramine.

Authors:  J G Douglas; J F Munro; A H Kitchin; A L Muir; A T Proudfoot
Journal:  Br Med J (Clin Res Ed)       Date:  1981-10-03
  5 in total
  15 in total

1.  Fenfluramine--induced irreversible pulmonary hypertension.

Authors:  I Fotiadis; T Apostolou; A Koukoulas; N Michelacakis; D Kremastinos
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

2.  Myocardial infarction associated with the use of dextrofenfluramine.

Authors:  P Evrard; A F Allaz
Journal:  BMJ       Date:  1990-08-11

Review 3.  Respiratory toxicities from stimulant use.

Authors:  T E Albertson; W F Walby
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

4.  A dangerous duo? A combination of common diet drugs (fen-phen) may lead to heart valve disease.

Authors:  D R Boughner
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

5.  Irreversible pulmonary hypertension after treatment with fenfluramine.

Authors:  J McMurray; P Bloomfield; H C Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-05

Review 6.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

7.  Pulmonary hypertension and dexfenfluramine.

Authors:  P Cacoub; R Dorent; P Nataf; J P Houppe; J C Piette; P Godeau; I Gandjbakhch
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Dietary pulmonary hypertension.

Authors:  J M Kay
Journal:  Thorax       Date:  1994       Impact factor: 9.139

Review 9.  The unrelenting fall of the pharmacological treatment of obesity.

Authors:  Guido Di Dalmazi; Valentina Vicennati; Renato Pasquali; Uberto Pagotto
Journal:  Endocrine       Date:  2013-05-16       Impact factor: 3.633

10.  Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.

Authors:  H Saner; H P Gurtner; R Preisig; A Küpfer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.